Characteristics | Number of trials (%) | P value | |
---|---|---|---|
Before to 2007 year | 2008–2017 year | ||
Trial phase | 0.048 | ||
Phase I/II | 10 (10.4) | 38 (21.0) | |
Phase II | 78 (81.3) | 122 (67.4) | |
Phase II/III | 0 (0) | 4 (2.2) | |
Phase III | 8 (8.3) | 17 (9.4) | |
Sponsor | 0.215 | ||
NIH | 16 (16.7) | 17 (9.4) | |
Industry | 20 (20.8) | 40 (22.1) | |
Other | 60 (62.5) | 124 (68.5) | |
Number of centers | 0.560 | ||
1 | 32 (33.3) | 65 (35.9) | |
2 | 1 (1.0) | 5 (2.8) | |
multicenter | 63 (65.6) | 111 (61.3) | |
Number of arms | 0.007 | ||
1 | 79 (82.3) | 117 (64.6) | |
2 | 13 (13.5) | 54 (29.8) | |
≥3 | 4 (4.2) | 10 (5.5) | |
Treatment allocation | 0.002 | ||
Non-randomized | 83 (86.5) | 126 (69.6) | |
Randomized | 13 (13.5) | 55 (30.4) | |
Masking | 0.024 | ||
Open-label | 94 (97.9) | 164 (90.6) | |
Double-blind | 2 (2.1) | 17 (9.4) | |
Region | < 0.001 | ||
United states | 77 (80.2) | 109 (60.2) | |
Europe | 18 (18.8) | 47 (26.0) | |
Asia | 1 (1.0) | 25 (13.8) | |
Therapy | |||
Chemotherapy | 55 (57.3) | 40 (22.1) | < 0.001 |
Target therapy /immunology therapy | 36 (37.5) | 130 (71.8) | |
other | 5 (5.2) | 11 (6.1) |